Physician profile
Rajasingam Jayasingam
NPI 1447409636
$2,107.20
in general payments reported to CMS, 2019-2025
17 companies · $14.08 in 2025
The $14.08 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $185 · 2021: $588 · 2022: $287 · 2023: $279 · 2024: $308 · 2025: $14.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $577.68 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $268.66 | 2019-2021 | |
| Janssen Products, Lp | $198.00 | 2021-2022 | |
| Viiv Healthcare Company | $170.68 | 2019-2023 | Rukobia |
| Paratek Pharmaceuticals, INC. | $168.71 | 2023-2024 | Nuzyra |
| Shionogi INC | $137.48 | 2024 | Fetroja |
| Melinta Therapeutics, LLC | $121.26 | 2024 | Rezzayo |
| Emd Serono, INC. | $107.51 | 2021-2022 | |
| Theratechnologies INC. | $100.44 | 2019-2021 | |
| Janssen Biotech, INC. | $92.44 | 2019-2023 | Symtuza |
| Cumberland Pharmaceuticals, INC. | $59.50 | 2023-2024 | Vibativ |
| Insmed, INC. | $38.53 | 2023 | Arikayce |
| Biogen, INC. | $14.56 | 2019 | |
| Acadia Pharmaceuticals INC | $14.08 | 2025 | Nuplazid |
| Glaxosmithkline, LLC. | $13.49 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $13.18 | 2023 | |
| Tetraphase Pharmaceuticals, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajasingam Jayasingam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.